Evidence map›Paper›PMID 40760325›Full record

SynthesisHormones (Athens, Greece)2025

Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes mellitus: a systematic review and meta-analysis.

Eleni Rebelos, Ioanna A Anastasiou, Nikolaos Tentolouris, Thomas Karagiannis, Apostolos Tsapas, Ele Ferrannini, Aris Liakos

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Hormones (Athens, Greece), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Revolutionizing Diabetes Care: From Tech to Therapeutics.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Eleni RebelosFirst Department of Propaedeutic Internal Medicine and Diabetes Center, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece. eleni.rebelos@utu.fi.
Ioanna A AnastasiouFirst Department of Propaedeutic Internal Medicine and Diabetes Center, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.
Nikolaos TentolourisFirst Department of Propaedeutic Internal Medicine and Diabetes Center, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.
Thomas KaragiannisClinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Apostolos TsapasClinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Ele FerranniniInstitute of Clinical Physiology, CNR, Pisa, Italy.
Aris LiakosClinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsWe conducted a systematic review to compare the efficacy and safety of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) versus placebo in addition to insulin treatment in patients with type 1 diabetes (T1D).

methodsWe searched the PubMed and Cochrane databases up to November, 2023. Randomized controlled trials (RCTs) with a duration of ≥ 12 weeks were deemed eligible for the primary outcome (change in HbA

resultsA total of 25 RCTs were eligible. Compared with placebo, use of GLP-1RA was associated with a reduction in HbA

conclusionThe addition of GLP-1RA on top of insulin therapy in people with T1D results in a modest reduction in HbA

Indexed as

Diabetes Mellitus, Type 1Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsInsulinDrug Therapy, CombinationHumansHypoglycemiaRandomized Controlled Trials as TopicGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsInsulinGLP-1 receptor agonistHbA1cType 1 diabetesWeight loss

Identifiers

PMID40760325
PMCPMC12678461

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.